#United States #datma #Beaverton #Real-World Data #patient journey mapping

datma Introduces Innovative Patient Journey Mapping Tool

Beaverton, Oregon – datma, a forerunner in the domain of federated real-world data access, has recently unveiled groundbreaking patient journey mapping capabilities within its flagship structure, datma.FED. Tailored for pharmaceutical companies, this state-of-the-art functionality aims to grant a clearer perspective on how therapies are embraced in real-world healthcare scenarios.

Patient journey mapping sheds light on the intricate pathway patients traverse within the healthcare system, spanning from initial diagnosis to the commencement of therapy and thereafter. This new development is pivotal for pharmaceutical teams, enabling them to pinpoint obstacles that hinder timely interventions, comprehend care deficiencies, and assess the variations in healthcare provider decision-making.

Enhancing Insights While Maintaining Privacy

A significant feature of this mapping tool is its ability to conduct structured and compliant analyses of patient timelines that integrate clinical, genomic, and diagnostic data. This approach not only respects patient privacy but also safeguards institutional governance. Robin Edison, Vice President of Product at datma, remarked, “This launch represents a vital advancement in allowing pharma teams to gain insights into the transitional stages that patients experience from diagnosis to treatment. It uncovers where patients drop off, how decisions are made by providers, and why disparities arise across different healthcare environments.”

From Complexity to Clarity

Datma's innovative mapping capability harnesses large language models (LLMs), which adeptly extract structured timelines from both unstructured and structured data sources. These include clinical notes, medication records, and molecular panels. By categorizing, timestamping, and transforming these data into coherent sequences, the patient journey can be objectively analyzed. Clustering methods are employed to identify common treatment patterns, facilitating comparisons across diverse clinical environments or patient demographics.

Moreover, all analyses take place within datma.FED's federated framework. This ensures that data remains in compliance, held securely within the relevant institutions' infrastructure. The journeys are computed locally, anonymized into numerical representations, and then analyzed in aggregate form. This methodology enables health systems to gain valuable insights without having to transfer sensitive patient information.

Comprehensive Mapping Capabilities

With the launch of this feature, datma.FED supports:

• - Mapping diagnostic and treatment sequences across different institutions.
• - Identifying points where patients face delays, discontinuances, or shifts in therapy.
• - Analyzing variations in care across different physician networks and geographical areas.
• - Evaluating treatment sequencing and real-world usage trends.

As part of datma.FED’s extensive federated platform, patient journey mapping aligns perfectly with institutional privacy policies and governance measures. This empowers a collaborative environment among health systems, labs, and pharmaceutical entities, paving the way for richer, actionable healthcare data insights.

To delve deeper into the benefits of patient journey mapping via datma.FED, visit this link.

About datma

Founded with the mission to unlock the potential of decentralized healthcare data, datma stands as a leading provider for federated Real-World Data platforms and analytical tools. Their flagship product, datma.FED, combines artificial intelligence with federated query capabilities to facilitate a secure and efficient data-sharing marketplace targeting improved patient outcomes globally. Headquartered in Oregon, datma is dedicated to evolving how healthcare data is utilized, thereby enabling meaningful and compliant collaborations.

For more insights and updates, visit datma's official website.